On 25 May 2018, orphan designation (EU/3/18/2027) was granted by the European Commission to Regeneron Ireland U.C., Ireland, for three human monoclonal antibodies against the EBOV glycoprotein (also known as REGN3470-3471-3479) for the treatment of Ebola virus disease.
In December 2019, Regeneron Ireland U.C. changed name to Regeneron Ireland DAC.
Three human monoclonal antibodies against the EBOV glycoprotein
|Disease / condition||
Treatment of Ebola virus disease
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;